compounded semaglutide difference is compound being discontinued The End of Semaglutide: Why the FDA's Decision Matters for Patients and Pharmacies Compounded semaglutide vs. Wegovy

Meconium obstruction in absence of cystic fibrosis in low birth weight infants: an emerging challenge from increasing survival

: , , As hopeful as this is, a few big questions remain, especially if we care about equity and not just headlines: - Will oral GLP-1s actually be covered by insurers and employers as long term therapy, instead of short weight loss sprints followed by predictable regain - How will pricing and step edits work when a patient has already been on an injectable for more than a year - Will these trials and future studies meaningfully include the diverse, underrepresented communities that carry a disproportionate burden of obesity, sleep apnea, and cardiometabolic disease : - Set expectations early: discuss obesity as chronic disease, and proactively plan for maintenance before stopping anything

Addressing Patient Concerns and Protecting Their Rights Patient concerns are common during clinical trials, and it is essential that these concerns are acknowledged and addressed promptly

doi: 10.1099/ijsem.0.004107 148 ZhouZ

18 ,